Denmark: Novo Nordisk has announced that Lars Fruergaard Jorgensen will step down from his role as CEO of Novo Nordisk. He ...

In an abrupt and surprising twist, the CEO of Ozempic-maker Novo Nordisk has been ousted from his position as the head of the ...

COPENHAGEN/LONDON (Reuters) -Years before Novo Nordisk's obesity drug Wegovy became a U.S. blockbuster, then-CEO Lars Rebien ...

NVO stock declines 3% as the company announces that Lars Fruergaard Jorgensen will be stepping down as the CEO.

Novo Nordisk NVO announced the surprise resignation of its chief executive officer (CEO), Lars Fruergaard Jørgensen. Sanofi ...

The Novo Nordisk Foundation started a dialog with Novo’s board “on the merits of an accelerated CEO succession,” Novo said, ...

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Novo Nordisk's CEO, Lars Fruergaard Jorgensen, will step down amidst market challenges and a significant stock price drop, exceeding 50% since June 2024. Increased competition from compounded ...

Despite early success, however, Novo Nordisk has fallen behind in the GLP-1RA race, overtaken by Eli Lilly and its GLP-1RA ...

The British magic circle law firm Freshfields revealed it was serious about a US expansion when it poached star M&A lawyer ...

Lars Fruergaard Jorgensen is being forced out after the Danish firm's board came under pressure from the foundation that controls the company. The shake-up follows Novo's leading position in the ...

Novo Nordisk CEO Lars Fruergaard Jørgensen will step down after eight years at the helm, as the Danish pharmaceutical giant ...